Increased CTLA-4 + T cells and an increased ratio of monocytes with loss of class II (CD14 + HLA-DR lo/neg) found in aggressive pediatric sarcoma patients

Journal for ImmunoTherapy of Cancer

Allan B. Dietz²  Matthew J. Seidel¹  James Williams⁴  Francis Eshun⁴  Masayo Watanabe⁴  Roberta H. Adams⁴  Paul Dickman⁵  Michael P. Gustafson³  Mary L. Maas³  Pooja Hingorani⁴ 

[1] Orthopedic Oncology, Scottsdale, AZ, USA;Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, and Division of Immunology, Mayo Clinic, Rochester, MN, USA;Human Cellular Therapy Lab, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester 55905, MN, USA;Center for Cancer and Blood Disorders, Phoenix Children’s Hospital, Phoenix, AZ, USA;Department of Pathology, Phoenix Children’s Hospital, Phoenix, AZ, USA

关键词: Lymphocytes;    Monocytes;    Immune suppression;    Immune phenotype;    Ewing sarcoma;    Osteosarcoma;   

Others  :  1225065
DOI  :  10.1186/s40425-015-0082-0

 received in 2015-03-13, accepted in 2015-07-15,  发布年份 2015

【 摘 要 】

Background

There is little information regarding the composition of peripheral blood immunity in sarcoma patients and even less in the context of pediatric sarcomas. We describe the immune status using flow cytometry of peripheral blood in patients with osteosarcoma and Ewing sarcoma and demonstrate excessive CD14 in tumor tissues.

Methods

Peripheral blood from patients with OS and ES was collected at diagnosis or relapse, and used for immune phenotyping of 74 different leukocyte phenotypes. Blood from young adult healthy volunteers was collected as controls. Tumor tissues were analyzed by immunohistochemistry.

Results

Nineteen patients (average age = 14 y) and 16 controls (average age = 25y) were enrolled on study. Of the 74 phenotypes, 14 were different between sarcoma patients and HV. Sarcoma patients’ leukocytes contained a higher percentage of granulocytes (67 % sarcoma vs. 58 % HV; p = 0.003) and fewer lymphocytes (20 % sarcoma vs. 27 % HV; p = 0.001). Increased expression of CTLA-4 was seen in both T cells in sarcoma patients as compared to HV (p = 0.05). Increased CD14 ⁺  HLA-DR ^lo/negimmunosuppressive monocytes were seen in sarcoma patients (p = 0.03); primarily seen in OS. Increased tumor necrosis factor receptor II expression was seen on CD14 ⁺cells derived from sarcoma patients as compared to HV (p = 0.01). Massive infiltration of CD14 ⁺cells was seen in OS (>50 % of cells in the majority of tumors) compared to ES (<10-25 % of cells). In contrast, both OS and ES had limited T cell infiltration (generally <10 % of cells).

Conclusions

Pediatric sarcoma patients exhibit several immune phenotypic differences that were exacerbated in more severe disease. These phenotypes have the potential to contribute to immune suppression and may indicate potential targets for immune therapies.

【 授权许可】

   
2015 Hingorani et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115:1531-1543.
• [2]Herzog CE. Sarcomas in adolescents and young adults: a summary of a recent symposium. J Pediatr Hematol Oncol. 2005; 27:177-178.
• [3]Chua I, Quinti I, Grimbacher B. Lymphoma in common variable immunodeficiency: interplay between immune dysregulation, infection and genetics. Curr Opin Hematol. 2008; 15:368-374.
• [4]Moore Dalal K, Antonescu CR, Dematteo RP, Maki RG. EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. Sarcoma. 2008:859407. doi:10.1155/2008/859407.
• [5]Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR et al.. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res. 2009; 15:4277-4287.
• [6]Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007; 13:5256-5261.
• [7]Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 2008; 8:10.
• [8]Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC et al.. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol. 2009; 218:222-231.
• [9]Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, Rosemann A et al.. A high proportion of bone marrow T cells with regulatory phenotype (CD4 + CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer. 2009; 125:879-896.
• [10]Ackermann B, Tröger A, Glouchkova L, Körholz D, Göbel U, Dilloo D. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin Padiatr. 2004; 216:176-182.
• [11]Guo W, Guo Y, Tang S, Qu H, Zhao H. Dendritic cell-Ewing’s sarcoma cell hybrids enhance antitumor immunity. Clin Orthop Relat Res. 2008; 466:2176-2183.
• [12]Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE et al.. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001; 61:8513-8519.
• [13]Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M et al.. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002; 38:158-164.
• [14]Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D et al.. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008; 14:4850-4858.
• [15]Appay V, Reynard S, Voelter V, Romero P, Speiser DE, Leyvraz S. Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods. 2006; 309:192-199.
• [16]Gustafson MP, Lin Y, New KC, Bulur PA, O’Neill BP, Dietz AB. Systemic immune suppression in glioblastoma: the interplay between CD14 + HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010; 12:631-644.
• [17]Chavan R, Salvador D, Gustafson MP, Dietz AB, Nevala W, Markovic SN. Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity. Cancer Immunol Res. 2014; 2:241-248.
• [18]Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC et al.. Immune monitoring using the predictive power of immune profiles. J ImmunoTher Cancer. 2013; 1:7. BioMed Central Full Text
• [19]Gustafson MP, Lin Y, Maas ML, Van Keulen VP, Johnson P, Peikert T et al.. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. PLoS One. 2015; 10: Article ID e0121546
• [20]Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14 + HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011; 117:872-881.
• [21]Gustafson MP, Abraham RS, Lin Y, Wu W, Gastineau DA, Zent CS et al.. Association of an increased frequency of CD14(+) HLA-DR(lo/neg) monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol. 2012; 156:674-676.
• [22]Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X et al.. Immunosuppressive CD14 + HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010; 70:443-455.
• [23]Gustafson MP, Lin Y, Bleeker JS, Warad D, Tollefson MK, Crispen PL, et al. Intratumoral CD14+ cells and circulating CD14 + HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. Clin Cancer Res. 2015;epub ahead of print.
• [24]Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER et al.. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003; 112:973-980.
• [25]Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K et al.. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pedatr. 1997; 130:388-393.
• [26]Tosato F, Bucciol G, Pantano G, Putti MC, Sanzari MC, Basso G et al.. Lymphocytes subsets reference values in childhood. Cytometry A. 2015; 87:81-85.
• [27]Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K et al.. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol. 2012; 12:5. BioMed Central Full Text
• [28]De Angulo G, Hernandez M, Morales-Arias J, Herzog CE, Anderson P, Wolff J et al.. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol. 2007; 29:48-52.
• [29]Moore C, Eslin D, Levy A, Roberson J, Giusti V, Sutphin R. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer. 2010;55.
• [30]Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother. 2007; 56:1037-1046.
• [31]Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Falà F, Fabbi M et al.. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005; 117:538-550.
• [32]Liu Y, He Z, Feng D, Shi G, Gao R, Wu X et al.. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011; 30:1051-1055.
• [33]Kawano M, Itonaga I, Iwasaki T, Tsumura H. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncol Rep. 2013; 29:1001-1006.
• [34]Laborde RR, Lin Y, Gustafson MP, Bulur P, Dietz AB. Cancer vaccines in the world of immune suppressive monocytes (CD14 + HLA-DRlo/neg cells): the gateway to improved responses. Front Immunol. 2014; 5:147.
• [35]Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al.. Identification of a new subset of myeloid suppressor cells in pheripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007; 25:2546-2553.
• [36]Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70:4335-4345.
• [37]Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B et al.. Immunosuppressive CD14 + HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. 2013; 27:377-388.
• [38]Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363.
• [39]Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al.. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369:134-144.